Patents currently prevent generic Viibryd (vilazodone) from being manufactured. The earliest a generic version could become available is in 2014, when the drug's first patent expires. However, certain factors could shorten or lengthen the exclusivity period of brand-name Viibryd, such as lawsuits or patents for other uses.
Viibryd™ (vilazodone) is a medication licensed to treat major depressive disorder, sometimes called clinical depression or major depression.
This medication is distributed by Forest Pharmaceuticals, Inc. Viibryd is protected from generic competition by patents that have not yet expired.
This first patent for Viibryd expires in September 2014. This is the earliest predictable date that a generic version could become available.
However, other circumstances could come up to extend or shorten this exclusivity period. This could include such things as lawsuits or other patents for specific Viibryd uses. Once the patent expires, there may be several companies that manufacture a generic Viibryd drug.
No, vilazodone is the active ingredient in Viibryd, but is not a generic version of it. What can be confusing is that the active ingredient of a drug is often referred to as the "generic name."
The generic name is different from a generic version of a medicine. In order for there to be a generic version of a medicine, the original medicine must have gone off-patent and another company besides the original manufacturer must make the product.